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ABSTRACT
Rheumatoid Arthritis: A Literature Review and Comprehensive Treatment Analysis
Charlie Mechling
Director: Jonelle Hook, PTA MA

Rheumatoid arthritis (RA) is a systemic and debilitating autoimmune disease. The
varying levels of severity of rheumatoid arthritis make it notably unique. Rheumatoid
arthritis is not strictly an inflammatory disease of the joints; it is an extensive disease
with many extra-articular manifestations that complicate its treatment and management.
In addition to being a disease that is internally driven by the body’s immune system,
current research reveals the pervasive influence of environmental factors on the disease’s
severity and activity. This literature review examines the pathophysiology of RA, its
implications on the body, and current treatment options to ameliorate some of its
symptoms and complications. A particular focus on the efficacy and potential value of
diet, psychosocial interventions, physical activity, and therapeutic modalities is central to
the current work. Evidence using a literature review of peer-reviewed articles discussing
RA and its many facets is utilized. A survey of patients with RA reveals patient attitudes
and discretions towards their arduous personal experiences with rheumatoid arthritis.
Overall, the findings indicate that having a well-versed interprofessional team of
physicians and health professionals supporting patients with rheumatoid arthritis using an
integrated model of care, is critical to improved overall well-being and disease outcomes.
KEYWORDS: Rheumatoid Arthritis, Autoimmune, Treatment, Survey
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CHAPTER ONE
Introduction

Rheumatoid Arthritis (RA) is a common chronic inflammatory autoimmune
disease affecting over 1.5 million people in the United States, the majority of which are
females (Gibofsky, 2012). An immune response characterized by lymphocytes,
neutrophils, mast cells, synovial tissue cells, and platelet microparticles play a
fundamental role in the inflammatory process within the synovial fluid (Boilard et al.,
2010) leading to synovitis, joint deformity, and structural bone damage. This
inflammation can cause considerable levels of pain and swelling to the joints with
ensuing severe joint dysfunction. One of the most noteworthy symptoms of RA is the
presence of severe fatigue – which is far more intense and distinct than general fatigue
experienced by those without an RA diagnosis. Factors associated with heightened
fatigue levels among RA patients include medical-related issues, along with psychosocial
and lifestyle factors. These determinants include reduced social participation, lack of
sleep, decreased physical activity that is vital to overall well-being, and a sense of loss of
control over the prognosis (Nikolaus et al., 2010).
In addition, the economic burden of RA is extensive. The total medical costs
exceed $19 billion annually with many patients spending up to $30,000 a year on
medications alone (Freeman, 2018). The cost in medication ranges between 8 to 24% and
hospitalization constitutes anywhere between 17 and 88% of the total cost. Also, patients
report a median duration of up to 39 missed workdays annually (Burton et al., 2005).
Although research has helped formulate a better understanding of the condition, the
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underlying pathophysiology is still not fully understood. It is suggested that epigenetic
factors can ameliorate the interaction of genetic and environmental factors that contribute
to the complexity and lifelong complications of this disease. The severe extra-articular
manifestations and economic burden of this disease illustrate that it is imperative to use a
holistic approach. Incorporating various aspects of lifestyle modifications can ensure
better management of RA and its many manifestations.
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CHAPTER TWO
Pathogenesis and Pathophysiology

The pathogenesis and pathophysiology of RA are not well-defined. A
combination of biological markers and environmental factors complicate the
understanding of RA and its systemic effect on the body. In adults, RA is typically
classified into one of two types: seropositive rheumatoid arthritis or seronegative
rheumatoid arthritis. Blood tests identifying the presence of rheumatoid factor (RF) and
antibodies to citrullinated protein antigens (ACPAs) indicate seropositive RA (Nordberg
et al., 2016). Antibodies to citrullinated proteins are pathogenic autoantibodies produced
by B memory cells in the body’s humoral adaptive immune system. The adaptive
immune system is characterized by lymphocytes, T and B cells, and dendritic cells that
target pathogens in the body. Antibodies to citrullinated proteins are highly specific for
RA because they attack extracellular citrullinated protein antigens that are produced in
response to inflammation in body tissues and organs (Derksen et al., 2017; Surmont &
Diamond, 2015). Recent studies suggest that the presence of these autoantibodies may
inadvertently amplify inflammation, directly enhancing arthritis in the body (Elkon &
Casali, 2015). Various sources indicate that these autoantibodies may be present years
before the onset of RA-related symptoms occur, signifying the potential for systemic
effects of RA that cannot be determined by clinical phenotypes (Brennan & Mcinnes,
2008; Suurmond & Diamond, 2015).
In contrast to seropositive RA, seronegative RA patients are ACPA negative. In
2010, the American College of Rheumatology redefined the classification criteria for
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seronegative patients. The criteria deemed that seronegative patients must show
inflammation in 10 or more joints to meet the criteria for an RA diagnosis. Joint
inflammation occurs when the immune system attacks and thickens the synovium lining
around the joints. If inflammation around the joints persists, the cartilage and bone within
the joint can be permanently damaged.
Historically, seropositive RA has been considered to be more severe than
seronegative RA, but recent findings propose otherwise. A 2016 report in the Annals of
the Rheumatic Diseases found that in a study of 234 patients with either a seropositive or
seronegative RA diagnosis, the seronegative patients reported higher disease activity in
comparison to the seropositive patients (Nordberg et al., 2016). This insight could be of
interest to diagnosing physicians and rheumatologists as swollen joints and the presence
of ACPA may not be the most useful factors in identifying the severity of disease. Further
research should be enacted to determine the varying severity levels of seropositive versus
seronegative RA and their criteria for diagnosis.
The second component that adds to the complexity of the development and
progression of RA is the interaction between the body’s immune response to
environmental factors. Smoking, infectious agents, periodontal disease, the
gastrointestinal microbiome, and adverse life events are all related to the onset of
rheumatoid arthritis (McInnes & Schett, 2011). Reports indicate that smoking, one of the
strongest known risk factors for RA, may perpetuate the production of citrullinated
proteins, resulting in the subsequent development of ACPAs (Demoruelle & Deane,
2011). The interaction between what the body experiences externally and how it reacts
internally increases the variance in predictors for disease activity and complicates the
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understanding of the pathogenesis of RA. As new research and information regarding the
biological and environmental factors that impact the disease become available, a better
understanding and appreciation for the chronic, and sometimes invisible, effects of RA
are likely to result.
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CHAPTER THREE
A Systemic Disease

Rheumatoid arthritis is predominantly classified by its manifestations and
physical phenotypes in the major joints of the body. When people think of “arthritis,”
they think of bone atrophy, aging, inflammation, and fatigue. While each of these factors
play a role in the course of this chronic autoimmune disease, new research indicates that
the underlying systemic involvement of RA is much greater than previously thought.
According to Prete et al. (2011, p.124), “The natural history of the disease in most
patients involves chronic low-grade inflammation, with periodic flares, that may
progressively lead to joint destruction, deformity, disability and even premature death.”
Yet, the overall effects of the disease appear to be much more intense than the symptoms
that result from low-grade flares of inflammation.
Fatigue, for example, was at one time considered to be a primary symptom related
to elevated levels of inflammation in the body. More recently, researchers believe fatigue
to be associated with other RA-related symptoms, including depression, anxiety, and the
inability to exercise (Moreland & Curtis, 2009). These psychosocial factors influencing
disease activity suggest the personal burdens associated with an RA diagnosis are more
far-reaching than presumed by early research.
Other indicators such as the presence of rheumatoid nodules and constitutional
symptoms including fevers, highlight the misunderstanding of RA as being regarded as a
type of arthritis, rather than a systemic disease. Kelly O’Neil Young, author of the book,
Rheumatoid Arthritis Unmasked: 10 dangers of Rheumatoid Disease, provides a great
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amount of research regarding the symptoms of RA that go beyond joint inflammation.
She highlights how the Mayo Clinic lists fever as one of the primary symptoms of
rheumatoid arthritis (Rheumatoid arthritis, 2019), and yet most patients who visit their
primary care physicians or rheumatologists rarely, if ever, have their temperatures taken
upon arrival (Young, 2017). A low-grade fever may indicate RA activity and subsequent
flare-ups, even if there are no signs of physical inflammation or swollen joints. Similarly,
rheumatoid nodules are a symptom of RA that “can form before joint involvement and
may be associated with an increased risk of other extra-articular manifestations” (Prete et
al., 2011, p.126). These nodules are subcutaneous and occur in roughly 30% of RA
patients (Prete et al., 2011, p.126). Because rheumatoid nodules can develop before joint
involvement, clinicians may not be aware of disease activity if a more thorough
examination of the patient’s symptoms is not completed.
Current research suggests that the extent of disease activity in RA patients may be
much more difficult to determine than once thought. This is critical for clinicians and
researchers to consider as they move forward in determining the future of RA treatment
and the clinical evaluation of the disease. Patients may be suffering from the systemic
symptoms of RA without showing any signs of inflammation in the joints. This likely
means that numerous patients could be misdiagnosed or receive treatment for RA
considerably later than what is recommended by physician-researchers. Like most other
chronic diseases, the early treatment and diagnosis of RA is crucial in preventing
significant progressions and retarding the long-term severity of disease (Heidari, 2011).
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CHAPTER FOUR
Articular Manifestations

Articular (pertaining to a joint or joints) inflammation and destruction due to RA
is generally considered to be the primary symptom indicating disease activity. The
destruction of the joints can lead to functional decline and increase the risk of
comorbidity in various systems in the body (Brennan & Mcinnes, 2008). Clinicians look
for symmetrical inflammation of the small joints in the hands and feet during an initial
evaluation of patient symptoms (Weissman et al., 2018). Synovial inflammation can
become so severe that the patient experiences a drastic decrease in muscle mass, referred
to as rheumatoid cachexia. Studies suggest that rheumatoid cachexia is directly related to
the presence of pro-inflammatory cytokines in the joints of patients with RA (Santo et al.,
2018).
Cytokines are proteins released by cells that interact with other cells. Cytokines
can be either anti-inflammatory or pro-inflammatory, with evidence supporting that
specific pro-inflammatory cytokines are directly involved with pathogenic pain (Zhang &
An, 2007). The elevated presence of cytokines in inflamed joints serve as helpful
biomarkers for therapies directed towards mitigating the progressive destruction of the
joints and extreme muscle loss seen in patients with rheumatoid cachexia. Understanding
the influence of cytokines on the primary articular manifestations of RA is paramount
towards formulating therapies that both attack pro-inflammatory cytokines to prevent
destruction, and also to limit pathogenic pain (Zhang & An, 2007). Reducing patient pain
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and fatigue is key to hindering the magnitude of co-morbidities and extra-articular
manifestations that tend to develop throughout the disease.
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CHAPTER FIVE
Extra-Articular Manifestations

Extra-articular manifestations are the associated symptoms and conditions of RA
that are not related to the articular joints or musculoskeletal system of the body (Cojocaru
et al., 2010). While these are considered secondary symptoms to the articular
manifestations in the synovial linings, they are not to be confused with complications.
Approximately 40% of RA patients present extra-articular symptoms, with the onset
occurring at any stage in the disease and with the likelihood of occurrence equal amongst
both men and women (Cojocaru et al., 2010; Weissman et al., 2018). The extra-articular
manifestations in RA patients most commonly and severely impact the heart, lungs,
larynx, and vascular systems. Involvement with extra-articular organs positively
correlates with the severity of the disease, contributes to increased mortality, and is
influenced by genetic and environmental factors. (Cojocaru et al., 2010; Prete et al.,
2011). The extra-articular involvement within the major organs of the body make these
secondary symptoms of RA dangerous and yet are often overlooked. A discussion
regarding the severity of the complications associated with extra-articular manifestations
will be reviewed, along with an explanation of how environmental and genetic risk
factors complicate symptoms.
Rheumatoid arthritis patients often present with phonatory (of speech and sound)
and respiratory symptoms that can be subtle and misleading, resulting in seldomly made
diagnoses and treatment plans. Inflammation of the cricoarytenoid joint in the larynx can
produce symptoms such as loss of voice, hoarseness, pain in the throat, vocal cord
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dysfunction, immobility, and fixation (Young, 2017). Recent studies show that laryngeal
involvement is seen in up to 90% of RA cases, with up to 50% of patients reporting that
laryngeal inflammation is the sole manifestation of their RA symptoms (Hamdan &
Sarieddine, 2013). While most laryngeal symptoms are not life-threatening, they can
impact and restrict one’s quality of life. Aphonia, the loss of the ability to speak, results
from inflammation in both vocal cords (Hamdan & Sarieddine, 2013). Rheumatoid
arthritis patients who experience this type of disruption to their vocal cords must visit a
clinician for treatment of the symptoms. In addition, patients who present with laryngeal
symptoms and no articular symptoms may be in the early stages of RA, and the early
detection of inflammation in the vocal cords could lead to a better disease prognosis
(Young, 2017). However, a few clinical autopsies have found that rheumatoid
cricoarytenoid arthritis is not always clinically detectable (Young, 2017). This can lead to
a lack of awareness of laryngeal involvement and a subsequent delay in therapy.
As with laryngeal involvement, pulmonary RA manifestations can generate a
wide spectrum of symptoms and disorders. The most common pulmonary manifestations
are interstitial lung disease, rheumatoid nodules, and pleural effusions (Gauhar et al.,
2007), with 50% of patient cases reporting pleural involvement and only 10% being
clinically detected (Cojocaru et al., 2010). Researchers are beginning to explore the role
of inflammatory cytokines (the proteins found in the inflamed synovia of RA patients) to
determine their involvement in pulmonary inflammation. While the exact effect of
cytokines in pulmonary inflammation is not well-understood, further investigations are
suggested to explore the role of cytokines in pulmonary involvement to formulate target
therapies (Moreland & Curtis, 2009). Likewise, in her book, Young describes how most
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studies have shown that there is no correlation between the degree of severity of articular
destruction and the extent of pulmonary involvement (Young, 2017). Thus, pulmonary
symptoms could be severe, while the clinical assessment of joint, cartilage, and bone
damage could potentially be mild. Without considering pulmonary involvement as an
indicator of rheumatoid activity, the clinical phenotypic observation of the joints would
fail to provide an accurate assessment of disease activity and severity.
In like manner to the heightened risk of developing pulmonary symptoms, the risk
of developing coronary artery disease and heart failure is twice as likely for patients with
RA and can be evident before an official RA diagnosis (Crowson et al., 2013, p. 622).
Recent literature highlights the critical role of inflammation of the vasculature and its
correlation with an increased risk of cardiovascular disease and mortality. Vascular
leakage and atherosclerosis are examples of two vascular diseases that result from
inflammation and a buildup of fatty material on the arterial walls. Both these diseases are
associated with RA and contribute to high cardiovascular risk. The inflammatory proteins
that cause synovitis, inflammation of the synovial linings of the joints, also attributes to
vasodilation of the blood vessels and a decrease in overall blood pressure (Szekanecz &
Koch, 2008).
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CHAPTER SIX
Genetic and Environmental Factors

While extra-articular manifestations can exist on their own or in conjunction with
another, genetic predispositions and environmental risk factors can exacerbate the
likelihood of developing RA, extra-articular manifestations, and increase mortality risk.
Recent research coins a term ‘Preclinical RA,’ where circulating levels of RF and ACPAs
are elevated in the bloodstream (Deane et al., 2017). This influx of autoimmunity defense
mechanisms can be present in the body long before the clinically apparent synovitis in the
joints. Because the propagation of autoimmunity may be present before an inflammatorybased RA diagnosis, the genetic and environmental risk factors associated with RA may
also be influencing the body and its systems far in advance of the swelling of the distal
joints. Among seropositive patients, the familial genome may contribute to 50% of the
risk of RA development (Deane et al., 2017). Within the overall genetic risk, new
findings show that a specific group of alleles called the ‘shared epitope’ may contribute
to 40% of the familial genome risk (Deane et al., 2017). The presence of these alleles is
highly associated with ACPA seropositive patients and are considered to be high-risk
alleles within the human genome. Additionally, environmental risk factors also influence
the rate of disease and its severity. While researchers don’t know exactly when these
environmental risk factors act in the natural history of RA, it is widely known that they
do have an effect on the disease over time.
Most notably, exposure to smoking and specifically to tobacco may account for
up to 30% of environmental risk in RA patients (Deane et al., 2017). The effect of
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smoking on the pulmonary system may attribute to high inflammation of the pleural
cavity with patients who experience symptoms from extra-articular manifestations in the
lungs. Further evidence also indicates that diet, the health of the microbiome, and
exposure to silica dust, are primary environmental risk factors for the development and
severity of RA (Badsha, 2018; Deane et al., 2017; Guahar et al., 2007).
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CHAPTER SEVEN
Pharmacological Therapy

Because the coordination of clinician involvement may be difficult to obtain for
RA patients who are suffering from symptoms of extra-articular manifestations, the
management and treatment of RA is overwhelmingly complex. Like many other chronic
diseases, rapid pharmaceutical intervention is most beneficial within the first 12 months
of the diagnosis. It has been established that many RA patients suffer from extra-articular
manifestations, which also require rapid and often long-term treatment. Over time, the
medications required of an RA patient can be difficult on the body. The most common
medications used to treat the underlying disease and symptoms of rheumatoid arthritis are
DMARDS (disease-modifying anti-rheumatic drugs), corticosteroids, and NSAIDS (nonsteroidal anti-inflammatory drugs) (Mota et al., 2013).
Disease-modifying anti-rheumatic drugs are immunosuppressive and
immunoregulatory drugs that are designed to slow the underlying progression of RA, not
just treat the symptoms (“DMARDS,” n.d.). Methotrexate is the most commonly
prescribed DMARD and is generally considered to be the first line of defense in treating
RA due to its well-established efficacy (Mota et al., 2013). While concerns surrounding
the use of methotrexate are focused on its long-term gastrointestinal effects, numerous
studies have found that methotrexate may also reduce cardiovascular activity in RA
patients (Crowson et al., 2013; Salliot & Heijde, 2008), adding to its benefits as a
disease-modifying agent. In 2013, the Brazilian Society of Rheumatology released a
report outlining the guidelines for the drug treatment of RA, with a specific focus on the
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use and safety of DMARDS. In their report, the authors state, “Early administration of
DMARD treatment (less than nine months from symptom onset) produced a 33% relative
reduction in the radiographic disease progression during the following three years” (Mota
et al., 2013, p.162). Due to their disease-modifying abilities combined with their
relatively safe effects on the body’s systems, DMARDS are the current standard for drug
treatment against RA. When combined with other symptom-suppressing medication,
DMARDS prove to be overtly suitable for treating RA.
Corticosteroids are a class of steroid-based drugs that target inflammation and
pain. Their role in the body is focused on improving RA symptoms, rather than treating
the underlying mechanisms of disease. While DMARDS can eventually treat symptoms if
they are able to slow disease progression, symptom relief is not immediate.
Corticosteroids target symptoms directly, resulting in fast relief. Prednisone is a wellknown corticosteroid that is commonly prescribed for RA patients. While effective at
treating symptoms, prednisone has many side effects that contradict long-term usage
(“Prednisone,” n.d.). Patients who are prescribed high doses of prednisone are at twice
the risk of developing cardiovascular disease than those who are not prescribed a steroidbased anti-inflammatory (Crowson et al., 2013, p. 624). Unless the progression of RA is
static and under control, prednisone and other corticosteroids are not typically prescribed
alone. Medical research suggests that the pharmacological treatment of RA is most
successful when low doses of prednisone are used in combination with DMARDS or
other disease-modifying medications to combat both the disease itself and its symptoms
(Mota et al., 2013).
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Non-steroidal anti-inflammatory drugs are anti-inflammatory medications that
like corticosteroids, decrease inflammation and pain. Non-steroidal anti-inflammatory
drugs, however, are unique because they do not contain steroids. While they are
considered to be safer for long-term use, they are not as effective at managing symptoms.
Common NSAIDS that are used to treat RA symptoms are Aspirin, Ibuprofen, and
Meloxicam (Freeman, 2018). Even though the strength of NSAIDS is far less comparable
to that of corticosteroids, physicians consider renal, hepatic, and cardiovascular adverse
long-term effects when prescribing NSAIDS to patients. Depending on the severity and
progression of disease, some RA patients may respond well to only taking an NSAID,
though prescribed NSAIDS are of much greater strength than over-the-counter antiinflammatory drugs. If the patient responds well to NSAIDS and does not have
worsening symptoms, research suggests that in combination with DMARDS, the use of
NSAIDS is a favorable pharmaceutical treatment plan (Mota et al., 2013).
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CHAPTER EIGHT
Non-pharmacological Therapy

Despite recent advances in the pharmacology realm of rheumatoid arthritis
treatment, a comprehensive approach including non-pharmacological treatment plans and
an interprofessional team of physicians should be the accepted protocol towards treating
RA and its extra-articular manifestations. Even when medicine-based treatment plans are
effective at abating disease progression or decreasing pain, a patient’s quality of life may
still be severely impacted. Lifestyle changes, exercise, therapeutic modifications,
psychosocial interventions, patient education, and alternative medicines are just a few
examples of non-pharmacological treatment options that are becoming increasingly
popular in treating RA. Empirically-supported research strongly suggests exercise,
psychosocial treatment, and patient education/self-management systems to be distinctly
significant in improving patient outcomes and enhancing quality of life (Cunningham &
Kashikar-Zuck, 2013; Vlieland, 2007). Patients tend to recognize the importance of
taking strong medications to fight the progression and symptoms of RA. At the same
time, however, patients also often wish that they could mitigate their usage of these harsh
pharmacology treatments to abate their strong side effects. In 2004, a group of
investigators published a study with 29 patients who had either begun taking a DMARD
for the first time or switched to an alternative DMARD. These patients were asked to
voice their opinions and beliefs regarding their medication and what implications it had
on their quality of lives. The investigators concluded that while DMARDS were believed
to be central to many of the patients’ treatment plans, patients voiced concerns regarding
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the long-term effects and potential ‘toxicity’ of their medications (Goodacre, 2004).
These complex beliefs regarding the feasibility and longevity of pharmacology treatment
may be of interest to researchers, physicians, rheumatologists, and scholars who are
looking to evolve the medical approach to RA treatment. At this point, obtaining a
multifaceted proposal to RA treatment is beginning to gain ground amongst
professionals. A more in-depth discussion of possible non-pharmacological treatment
options is described below.

Diet
Many patients with RA explore diets and other integrative modalities as a way to
control the disease process. Although the connection between RA and diet is still poorly
understood, it is estimated that about half of RA patients will try dietary modifications at
some point following their diagnosis (Badsha, 2018, p. 19). This is a logical next step as
scientific findings have shown a compelling link between the gut microbiome and its
influence on the immune system. Specifically, the filamentous bacteria in the gut tend to
drive the inflammatory process through its effect on helper T cells which then activate B
antibodies, resulting in the synovial inflammatory response (Badsha, 2018). Dietary
changes can either exacerbate or improve disease activity via their impact on the human
intestinal microbiome. For example, Lectin, a legume protein, has proven to influence the
pro-inflammatory response; while Genistein, a hormonal compound also present in
legumes, has been shown to inhibit pro-inflammatory cytokines (Badsha, 2018). Current
research most notably reports the positive influence of polyphenols, n-3 polyunsaturated
fatty acids (n-3 PUFAs), and monounsaturated fatty acids in RA activity suppression. A
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2018 study by Skoczyńska & Świerkot found that RA patients consuming foods such as
fatty fish, which contain high amounts of n-3 PUFAs, saw a significant decrease in
disease activity. Therapeutic fasting, another modality, could help improve the pain and
stiffness commonly seen in RA by improving gastrointestinal tract permeability and
modulating the inflammatory process (Hafström et al., 1988; Nair, & Khawale, 2016;
Sköldstam et al., 1979). While additional research should be conducted to better
understand the role of diet in RA disease activity, the results of current findings are
promising indicators of successful outcomes from dietary modification.

Physical Activity
The importance of maintaining a regular physical activity regimen for patients
with RA is critical towards sustaining overall well-being and cardiovascular health
(Cooney et al., 2011; Metsios et al., 2007). A 2015 study by Salmon and colleagues
examined the views of seven physiotherapists and two occupational therapists regarding
physical activity and its effect on RA disease progression. Researchers agree that
physical activity not only has a positive effect on mitigating fatigue in RA patients, but it
also helps improve patients’ psychosocial and overall well-being (Salmon et al., 2015).
However, it is noted that patients tend to exhibit limited physical activity due to several
factors. Some of these factors include negative patient perceptions regarding the effect of
exercise, lack of strength, persistent fatigue, and limited functioning (Cooney et al.,
2011). Physically inactive patients increase their risk of developing cardiovascular
disease and/or rheumatoid cachexia. Several research studies provide substantial evidence
that a combination of aerobic and strength training can drastically reduce disease activity

20

as well as provide additional benefits to the patient by improving functional ability and
reducing complications. Improvement in cardiovascular, musculoskeletal, and joint
health - as well as a reduction in pain and morning stiffness has been noted (Cooney et
al., 2011). Engaging in high-intensity resistance training is a safe and effective way for
patients to reverse muscular atrophy and restore strength. Additionally, aerobic exercise
such as walking, cycling, and swimming can improve cardiovascular fitness and address
symptoms of pain and fatigue (Cooney et al., 2011)

Therapeutic Modalities
Therapeutic approaches, such as occupational therapy and physiotherapy, are
essential parts of any RA treatment plan. The lack of autonomy associated with a reduced
ability to execute activities of daily living can have a profound impact on a patient’s
emotional and psychological state. To address this issue, a 2015 report emphasized four
critical areas for occupational therapists (OTs) to focus on during their evaluations of
patient priorities: patient guidance and education, joint protection and energy
conservation, modifying activity and work environments, and implementing the use of
assistive technologies (De Almeida et al., 2015). Occupational therapists play an integral
role within the multidisciplinary team to aid patients as they integrate daily approaches
that minimize difficulties in performing daily tasks. Additionally, physiotherapy
modalities, including hot/cold treatments, electrical stimulation, and hydrotherapy, are
commonly used in RA treatment. While research does not suggest physiotherapy to have
a direct effect on the clinical diagnosis, the objectives of this modality include disability
prevention, increasing functional capability, pain relief, and patient education (Kavuncu
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& Evcik, 2004). Each of these objectives plays a critical role in improving patient
outcomes. While there is limited research on the overall effects of physiotherapy for RA
patients, its ability to improve patient well-being should be fully considered for future
research.

Psychosocial Interventions and Significance
Depression associated directly with RA is not well recognized, nor is it routinely
treated. Studies show that anywhere from 13-42% of RA patients suffer from major
depressive disorder (Margaretten et al., 2011). The combination of socioeconomic,
genetic, and RA disease factors influence the prevalence of depressive disorders amongst
the RA patient population. Specifically, long-term disability, limited function, and
systemic inflammation are all associated with the development of depression
(Margaretten et al., 2011). Moreover, ‘uncontrolled flares’ tend to exacerbate persistent
RA symptoms and can result in complete cognitive shutdowns and total social
withdrawals. A study in 2011 explored the attitudes of 67 RA patients concerning their
perspectives on the psychological and psychosocial impacts of symptomatic flare-ups. A
few patients in this study reported having “ear-shattering pain” even when no noticeable
swelling occurred (Hewlett et al., 2011, p. 71). Others described their limited function to
be unbearable, with one patient stating, “I can’t function like this. I’m hurting, I want to
kill myself” (Hewlett et al., 2011, p. 72). These statements reveal the intense and
devastating experiences of RA patients who are forced to endure the effects of
‘uncontrolled flares.’ These impacts on patient lifestyles, social participation, and overall
well-being are difficult to comprehend. Psychosocial and psychological interventions
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should be integral components to the treatment of rheumatoid arthritis. The far-reaching
systemic effects of this disease require professional involvement. While the emotional
and mental impacts of RA are often not adequately addressed, they cannot go without
being recognized. Cognitive approaches for patient therapy have shown to be successful,
but more research is required to fully undertake and mitigate the depressive effects of
RA.
The efficacy of cognitive-behavioral therapy (CBT) has been studied in various
settings and trials with patients who have RA. The behavioral component to CBT for RA
patients involves strategies to help patients find a balance between rest and exercise.
Cognitive approaches help patients to cope with the stress related to chronic illnesses and
to develop attitudes of optimism and realism regarding their diagnosis (Koulil et al.,
2018; Sharpe, 2016). Studies show that CBT is considered as one of the most effective
psychological approaches to managing RA-related pain, while additional strategies such
as mindfulness-based interventions can benefit RA patients with a history of depressiveepisodes (Sharpe, 2016). In addition to therapies designed to address the psychological
symptoms associated with RA, a 2010 meta-analysis of randomized controlled trials
examined self-regulation theory (SRT) and its effect on psychological variables, along
with its potential ability to increase physical activity in RA patients. Utilizing this active,
goal-directed approach to managing RA reduced depressive and anxiety symptoms far
more than in subjects who did not partake in the SRT trials (Knittle et al., 2010). It is
noteworthy to add that to optimize the efficacy of psychological approaches and to ensure
successful results, these methods should be utilized early on in the disease process
(Knittle et al., 2010).

23

CHAPTER NINE
Rationale

The findings of the literature review reveal the broad scope of RA as an
autoimmune disease and thus its complications for treatment. The systemic nature of RA
makes it a particularly difficult disease to not only diagnose, but to manage over time.
Despite advancements in the medical treatment of RA, patients still feel as though their
lives are adversely impacted by the disease and have difficulty rationalizing the risks and
side effects associated with strong pharmaceutical medications. While many nonpharmacological treatment options are becoming more widely utilized, their efficacy is
still not fully understood. Moreover, just because new and emerging treatments are
insufficiently supported by empirical-based research, it does not necessarily mean that
they will fail in ameliorating patient symptoms or that they will not become standardized
in the future. Therefore, a survey was developed to evaluate the experiences and opinions
of RA patients who had obtained official RA diagnoses. The survey was designed to gain
additional information regarding patient treatment plans and whether or not patients
deemed these plans to be effective in managing their RA symptoms or in achieving
remission. It also gave insight into how this disease has affected patients emotionally, and
whether they feel their symptoms have been adequately managed.
The understanding that many patients will not be diagnosed with RA when they
first notice symptoms was taken into consideration, along with knowledge of how genetic
and environmental risk factors may exacerbate symptoms and extra-articular
manifestations. It was expected that the majority of patients utilize pharmacological
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treatments and that many may have changed their treatment plans depending on how long
they have lived with the disease. The hope is for patients and professionals to gain an
increased awareness of the extensive and systemic nature of this disease beyond
inflammation of the distal joints. New research regarding treatment options that go
beyond the restrictions of a medical doctor should continue to be acknowledged and
researched. A holistic approach is essential to manage and treat such an impactful and
life-altering disease.
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CHAPTER TEN
Methods

Materials
The survey was created de novo by the author and approved by the Institutional
Review Board (IRB) at the University of South Dakota. It was conducted online via
Google Forms, an online survey collection tool. The IRB approval can be found in
Appendix B. The survey consisted of 15 multiple choice and free response questions. A
greater emphasis was placed on free response questions due to the variability in potential
answers.
The survey began by asking generalized questions regarding the individual’s
gender, age, ethnicity, and age at which they were diagnosed with RA. This was designed
to obtain an overall understanding of the demographics of the participant and was used to
compare to the national demographic RA statistics.
The survey progressed to gain more specific insight into each participant’s
experience with RA by asking questions regarding the type of RA they were diagnosed
with, how their diagnosis made them feel, and what their initial treatment plan entailed.
The respondents were asked to answer a free response question regarding whether or not
they had changed treatment plans throughout their disease and to provide an explanation
as to why they had or had not.
The final questions were created to determine what the participants felt had been
the most effective or least effective regarding their treatment plans. These free response
questions allowed participants to expand on their answers and provide insight as to how
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their diagnosis was affecting them currently. The final question asked the respondents to
disclose whether they felt their symptoms were under control. This was used to gain an
overall understanding of how participants viewed their disease at this exact point in time,
regardless of when they were initially diagnosed or how their treatment plans had
changed. The complete survey is included in Appendix D.

Procedure
The survey was distributed to the public via email and social media (i.e.
Facebook). Included in the invitation was a short description of the survey’s purpose, the
target group, and a link to the survey on Google Forms. The survey was designed only for
patients who had been diagnosed with rheumatoid arthritis; it is possible that the survey
could have been completed by a family member with more advanced computer skills, or
by an individual who had not received a proper RA diagnosis.
Individuals who opened the survey link were directed to Google Forms and
presented with a complete description of the survey and an informed consent form. All
participants were informed that their participation was voluntary and to be completed at
their leisure. Acceptance of the informed consent was implied if the respondent clicked
“yes” on the opening page to access the survey. No identifying data were collected from
participants ensuring that all responses were anonymous.
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CHAPTER ELEVEN
Patient Survey Results (n = 28)

Figures 2-4: Participant Demographics
*Question 1 formatted as participant informed consent

Male
29%

Female
Female
71%

Male

Figure 2. What is your gender?

7%

7%
11%

18-22
23-29
30-49

45%
30%

50-64
65+

Figure 3. What is your age?

28

0%
4%

7%
7%

African-American
(non-Hispanic)
Asian/Pacific Islander
White (non-Hispanic)
Latino or Hispanic
Native American or
Aleut

82%

Figure 4. To which racial or ethnic group(s) do you
most identify?

Figures and Questions 5-8: Patient Responses to Initial Diagnoses

5

Number of Patients

4
3
2
1
0
1-5

6-10

11-15 16-20 21-25 26-30 31-35 36-40 41-45 46-50 51-55

Age (years old)

Figure 5. How old were you when you were first
diagnosed with Rheumatoid Arthritis?

29

yes
18%

other
32%

yes
no
other

no
50%

Figure 6. Were you diagnosed immediatley after your
symotoms first appeared?

Figure 6. Responses to “other” option
“Other” Responses
I started noticing differences in my daily fatigue levels but thought I was just overworking myself. Once I
stepped back from a few responsibilities and the fatigue continued I made an appointment with my doctor
I had been exceptionally sore for a long while
No, I was just diagnosed recently
Shortly after
yes, but took 6 months to get into a Rheumatologist
Soon after, my knees and lower joints really blew up
I wasn't sure what was wrong until the symptoms got really bad
I had been having symptoms for a while, but I didn't realize their severity
I was misdiagnosed

25%

25%

Seronegative
Seropositive
Juvenile

14%

Other
36%

Figure 7. What type of Rheumatoid Arthritis were you
diagnosed with?
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Figure 7. Responses to “other” option
“Other” Responses
Unknown
I was diagnosed with Lupus
unsure
Tested positive for RF and ACPA
unknown
Dr. never specified
Ankylosing Spondylitis

Question 8 - How did this diagnosis make you feel?
Participant Responses
I didn’t really know what to think or how it would affect my life. I had to stop playing many sports which really
scared me
Depressed and anxious
sad but relieved
Anxious and worried
At first fearful, once I met my dr I felt better
very sad because I am very active
Relieved to have answers!
Glad to have a diagnosis for my symptoms. But also afraid of the medications to treat RA.
It didn’t affect my feelings until I was about 13 years old because it made me quit all my sports.
Scared
Ambiguous
Worried an unsure of how to best deal with it
Very scared, nervous, somewhat relieved to know what was wrong
Anxious, upset, wanting more information
Unsure, worried
Relived I had been fatigued for a very long time prior
Concerned
I didn’t think it was Lupus. I had to wait a long time to see a Rheumatologist before I got the proper diagnosis
I didn’t know RA was an autoimmune disease. I thought I was getting old WAY too fast
Relieved
Like I was getting older
happy to know what it was, scared for what was to come
Confused
A little anxious, but my doctor helped me to feel better about it
Worried, but glad to know I wasn’t going crazy
Concerned, but I knew where my fatigue was coming from
Annoyed as I have always been very active
Confused since my blood tests were not positive
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Figures and Questions 9-12: Patient Responses to Initial Treatment Plans
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Types of Treatment Plans

Figure 9. What did your initial treatment plan entail?

Figure 9. Responses to “other” option
“Other” Responses
Methotrexate
Cortisone injection under full sedation in both knees and ankles
18 Ecotrin aspirin a day

Question 10 - Have you changed the course of your treatment during the duration of your
diagnosis? Why or why not?
“Other” Responses
Yes, I originally was only taking Aleve to relieve the pain in my joints. The pain got worse around middle school
and I was briefly put on steroid medication (which I hated). I have now been taking Meloxicam for years and it
seems to work great.
Somewhat. I added attending a support group several months after being and eventually I’ve added massage and
acupuncture
Not really
Started with non-steroidal medicine but I am now taking Humeria one a week
We tried multiple medications till we found the biologic that worked. It took two years to gain control with
biologics and medical cannabis
Yes, I have changed drugs several times
Yes. Many times. Sometimes due to something not working effectively and other timed due to allergies
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Minimally. I take less methotrexate now since the disease is under control. I also take naproxen for pain control. I
take less than the recommended dose.
Yes because I had knees the size of softballs which made me paralyzed for a short time
Yes! So many new meds out today! Thank goodness!
Added an additional drug
I have added in some dietary changes to try to reduce inflammation. I have added some natural ant inflammatory
supplements to my routine
Yes, I have tried different drugs and exercise during flare ups. My OT has really focused on helping me with
small daily tasks that I am embarrassed to ask for help with like buttons, cutting food etc
yes, as it started to make my joints deteriorate, I had shoulder replacement surgery, have changed my exercise
habits and have changed medications
Yes,
Yes
No
Yes; different therapies, different medication
Yes, wasn’t seeing any change from the medications
Yes, I began receiving cortisone injections and they have worked quite well
Yes, I’ve researched many different anti-inflammatory diets and have yet to find one I like
Yes, I’ve changed medications
I’ve stuck with the same med for the past few years and they’ve worked great. I still see my OT but not too often
yes, I began taking methotrexate in my 20s and it has worked quite well. A few side effects but nothing too harsh
Yes, I am deeply involved with the treatment of Rheumatoid Arthritis. I have changed medications many times
and have developed my won remedies
Yes, I was taking methotrexate but found it to negatively affect my lungs
yes, I like to keep up-to-date on different DIY treatments along with non-steroidal medications

Question 11 – What have you found to be the most effective in regard to your treatment plan?
Participant Responses
Medication is best for immediate relief when I have a flareup. Finding support groups and others with my
diagnosis and talking with therapists to help with depression. Working with professionals to improve my ability
to do everyday things so that my boyfriend doesn't have to. Adding exercise to my life
rest
Fish oil supplements
remaining active even though some days you don't feel like it
My rheumatologist and I keep in touch. I just started on Humira and have found it to be beneficial thus far
Biologics
My medications
The addition of Humira actually put me in remission for two years a few years ago. Unfortunately the disease
became active again and I am now back on Humira with methotrexate. Also staying physically active is very key
to keeping the disease from being active
Methotrexate
Medical cannabis and swimming
Combination of all of the previous methods (meds, massage and acupuncture, exercise helps as well but I haven’t
been good at maintaining just because of time constraints, not arthritis)
Lifestyle Changes
Naproxen
surgery, medication changes, anti-inflammatory supplements and physical therapy after surgery was absolutely
necessary
Taking my medication daily, but also exercise! When I skip a few days of exercise, I am noticeably more stiff
and sore
Humeria or Enbrel
Celebrex
Therapy
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My Rheumatologist has been incredible. He is well aware of the many other manifestations RA can take in the
body
Drugs for pain, exercise for stiffness and better mental health and positivity
Heat!
THC oil
Rituxan was by far the best treatment and the easiest for me to tolerate
methotrexate, changing diet to eliminate high inflammatory foods
Humira
Medication, yoga, and fish oil supplements
Communication with my doctor
Exercise, change in diet
Cortisone injection under full sedation in both knees and ankles
18 Ecotrin aspirin a day

Question 12 – What have you found to be the least effective or most difficult to attain in regard
to your treatment plan?
Participant Responses
any major dietary changes
Pain free days
I've heard about changes to diet but I jus haven't been able to force myself to make any concrete changes to my
diet quite yet
None
Staying up to date on different at-home remedies. There are too many and they are always changing
nothing
Dietary changes are hard. Very busy professional. Eat out most nights
I am concerned about flareups returning and getting worse
Exercise
excursive regimens that don't hurt my back
Going to therapy - I never have time!
exercising regularly without running
At home remedies - I can't maintain
Consistent morning stretch routine
Getting in to see my doctor
Use of adaptive equipment. I've had several hand braces over the years and they are uncomfortable and a drag to
take on and off
some of the drugs I took
At this point, nothing
Non-steroidal medicines
Getting off prednisone
An exercise plan
Changes in diet
Changing my diet has been very hard. I a young and it is hard to afford healthy foods and hard to find the time to
prepare them. I am making small changes and adding new ones that I can manage with my boyfriend.
Meloxicam
Good diet
The side effects of the steriods and getting off them
Therapy
Dietary changes only because it is hard to change lifelong habits of eating certain foods
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Figures and Questions 13-16: Patient Responses Regarding Current Symptoms and
Attitudes

4%
25%

No pain
39%

Mild pain
Moderate pain
Severe pain
Worse pain
32%

Figure 13. Compared to when you were initially diagnosed, how
would you rate your pain today?

Question 14 – Are there any activities you can no longer pursue due to your Rheumatoid
Arthritis symptoms?
Participant Responses
running
I can no longer run because it puts a lot pf pressure on my knees. The same thing goes for really any activities
that require my body to sort of pound against the ground
Not really, except anything related to strength in my arms or putting weight on my wrists when they are bent at
90 degrees
not really, just tire out faster
I can do just about anything on a good day but I will be sore from it
I was an organist/pianist/accompanist for 25 years in churches. While I may still play the piano for enjoyment,
the level I was at is now gone
No. I stay very physically active, and I think this really helps not only my mental status, but my physical status as
well
Yes, all sports and bike riding
Running
None
Running or walking long distances, typing on a keyboard, holding items for any length time, lifting heavy things
Many. I also have to take several days off work whenever I have a flare up. The swelling and pain in my hands is
the worst because it makes working at a computer almost impossible. My employer is not sympathetic and thinks
I over state my diagnosis and pain. Anything using my hands has to stop during flareups. Very frustrating
No heavy pressure on my shoulders. No weight lifting, limited upper body movement with my arms and
shoulders
Downhill hiking
No
Running. It takes a long time for my body to warm up to begin exercising
It takes me a while to get up and moving in the am
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I do not lift as much weight as I use to
Sewing
My hands don’t grasp my outdoor tools like they used to
I’ve been wary to do many activities. It’s been a trial and error process of what causes pain and what does not
grasping pencils or moving quickly in the morning
I don’t do too many overhead movements when I work out. My shoulders can’t handle much
Just the typical “getting older” activities
I am not as active as I used to be. I no longer play basketball
Hike less

Other
14%

Yes

No
25%

Yes
61%

No
Other

Figure 15. Have you ever discussed how your Rheumatoid
Arthritis diagnosis might affect you personally or socially with
your primary care physician?
Figure 15. Responses to “other” option
“Other” Responses
Yes, but there weren’t many avenues to explore with other people
Briefly, after proper diagnosis by my Rheumatologist
Has little speech to discuss a determination of this possibility
My rheumatologist recommended I join the Arthritis Foundation fb page and I’ve been able to share my
experiences with others and vice versa
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Other
18%
No
7%

Yes
No
Yes
75%

Other

Figure 16. Do you currently feel your Rheumatoid Arthritis
symptoms are under control?

Figure 16. Responses to “other” option
“Other” Responses
Will require new shoulders again in ten years. Pain is manageable but the deterioration in the shoulder socket
continues
Occasional flare ups from time to time
Yes, the do have flareups every to often but I know how to control them
Somewhat. I feel my symptoms could probably be better managed
Somewhat. I wish I had more pain free days
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CHAPTER TWELVE
Discussion

The results and implications of this survey shed light on many of the challenges
RA patients face throughout their treatment. From facing unknown or misdiagnoses to
feeling overwhelming levels of anxiety, fear, and confusion, there is nothing “easy” about
navigating the world of rheumatoid arthritis and its extra-articular manifestations. In
total, 28 patients with RA participated in this survey. Many of the free response questions
required participants to elaborate on particular survey questions, allowing for a detailed
description of their personal experiences. The results of the survey depict the need for
additional research and acknowledgment of the extensive effects of this disease.
Rheumatoid arthritis’ name alone is misleading and confusing to many of those who are
diagnosed at young ages. The word “arthritis” generally implies aging and the subsequent
deterioration of the bones and joints. While inflammation, fatigue, and destruction of the
joints are all major effects of RA, its systemic impact on the body is what makes it
notably unique and is what differentiates it from other forms of arthritis. The results of
this survey demonstrate the complexity of this disease and its profound impact on each
patient as it takes on a chronic state within the body.
The respondent demographics aligned with national RA statistics. The majority of
participants were female and 82% identified as White. However, no participants of this
study identified as Native American or Aleut (see Figure 2), despite recent research
suggesting an increase in RA prevalence amongst Native tribes (Ferucci et al., 2005). The
28 respondents ranged in ages from 18 to over 65 years old, and while varying ages of
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initial diagnoses of RA were reported, the age ranges of 21-25 and 31-35 were the most
common (see Figure 5). A possible explanation for this is the fact that 45% of
participants fell between ages 60-64 and had likely been diagnosed in early to middleadulthood (see Figure 3).
In regard to the diagnoses of RA, the results of the literature review examined
how obtaining a formal diagnosis by a rheumatologist or primary physician can be a long
and frustrating process. For instance, for those patients who do not produce blood
samples with positive ACPA and RF factors, the diagnosing procedure is based solely
upon the clinical phenotypic observance of the distal joints. The literature review also
revealed that many other organ involvements, including that of the heart, lungs, and
larynx, may be indicative of the presence of RA without any swelling of the distal joints.
This information suggests that patients may be suffering from the onset of RA symptoms
without visible inflammation of the joints. Participants in this survey were asked to reveal
if they had been diagnosed immediately after first noticing their symptoms and the type
of RA they were diagnosed with. Alarmingly, 50% of participants answered “no” to
being immediately diagnosed, while 32% answered “other” (see Figure 6). Responses
within the “other” option included answers ranging from patients being misdiagnosed,
not realizing the extent of their symptoms, or not being able to make an appointment with
a rheumatologist for 6 months. Likewise, when asked the type of RA they were
diagnosed with, 36% of participants reported being diagnosed with seropositive RA, 25%
seronegative RA, 14% juvenile RA, and 25% reported “other” (see Figure 7). Similar to
the previous “other” responses, participants who elaborated in this section reported
answers ranging from not knowing their diagnosis, being misdiagnosed with Lupus, to
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their doctor never even specifying to them the type of RA their diagnosis entailed (see
Figure 7). This information is distressing considering that similar to many other chronic
diseases, treatment intervention of RA is most effective when the disease is detected
accurately and early in its progression (Heidari, 2011; Mota et al., 2013). In addition, the
fact that at least three participants did not know what type of RA they were diagnosed
with is incredibly unsettling. For treatment to be effective, the patient must understand
the full context of their diagnosis.
Similarly, the survey results disclosed pertinent information concerning the
emotional and psychological toll of RA. When asked how their diagnosis made the
participants feel, 23 participants reported feelings of worry, concern, anxiety, and
confusion (see Question 8). While few expressed relief in knowing where their pain,
fatigue, and symptoms were coming from, the overwhelming majority responded
otherwise. From the results of the literature review, it was expected for some of the
participants to not understand their diagnosis. When a young and seemingly healthy 30year-old is told they have “arthritis,” it would be surprising if they were not confused.
This is precisely why professionals should integrate the education of RA and its
differentiation from other forms of arthritis into their practice.
Along with this idea, Figure 15 depicts participant responses to whether or not
they had ever discussed how their RA diagnosis might affect them personally or socially
with a physician. 61% of participants responded “yes,” 25% “no,” and 14% responded
“other.” Among the “other” responses, one participant stated, ‘Yes, but there weren’t
many avenues to explore with other people’ (see Figure 15). These results signify that
while it is apt that 61% of patients had discussed with their doctors how their diagnosis
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might affect them personally or socially, the extent to what actions were taken after this
discussion is unknown. Because the prevalence of major depressive disorder is so high
amongst RA patients, this conversation between patient and doctor should be routine.
This and the availability of more information regarding a patient’s diagnosis should be
available to mitigate feelings of confusion and worry after the initial diagnosis is made.
Figure 9 and Questions 10-12 demonstrate information related to patient
perspectives regarding their treatment plans and how these plans have changed
throughout their disease. The results shown in Figure 9 depict that over 25 patients
reported pharmacotherapy as being included in their initial treatment plans. This survey
question allowed participants to answer more than one treatment plan; participants may
likely have chosen a multitude of answers to this particular question. Every treatment
option available for this question was utilized; however, dietary changes, psychosocial
interventions, and the use of adaptive equipment were each only reported as being
included by 3 participants. Four participants answered “other” and each elaborative
response within the “other” option included the pharmacotherapy use of methotrexate,
cortisone injection, and aspirin (see Figure 9). While these results confirm medicine to be
the ‘go-to’ option for initial RA treatment plans amongst the participants, the widespread
utilization of non-pharmacological options gives insight towards where the future of RA
treatment may be headed. Even if drug treatment is effective in slowing the progression
of disease or in alleviating patient symptoms, a patient’s quality of life may still be
adversely affected. An overwhelming amount of research highlighted in the literature
review revealed the positive effects of a comprehensive and holistic approach to the
treatment of RA (Cunningham & Kashikar-Zuck, 2013; Goodacre, 2004; Vlieland, 2007).
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Furthermore, when asked how many of the participants had changed the course of
their treatment plans since their initial diagnoses, 24 reported that they had changed
medications, while others stated that they had experimented with various self-treatments
or home remedies (see Question 10). Markedly, participant responses to what they felt
had been the most effective element of their treatment plans varied immensely. Among
the vast amount of answers claiming medication to be the most efficacious, methotrexate,
cortisone injections, and Humira were among the most popular (see Question 11).
Humira, while not included in the literature review, is a type of medication called a
biologic. Biologics are special forms of DMARDS that are often prescribed when a
conventional DMARD is not effective (Biologics, n.d.). Along with this, many responses
attested to the benefits of being active and consistent with daily lifestyle routines.
Namely, it is noteworthy to consider the vast number of patients who reported a
combination of treatments as being the most effective. While not overly popular among
participant responses, 2 patients reported the use of medical cannabis and THC oil as
being the most effective treatment modality (see Question 11). Because the benefits of
medical cannabis and THC oil are not empirically researched to the extent of other
medications and treatments, it is not well known how their use will impact RA patients
over time. Nevertheless, the first-ever cannabis-based medical trial for the treatment of
pain in RA was conducted in 2005; its results are worthy of further research. In a study of
75 patients, the researchers concluded that cannabis-based medicine produced “a
significant analgesic effect and disease activity was significantly suppressed” (Blake et
al., 2005, p. 51). While information and support concerning the use of cannabis in its
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many forms are new and forthcoming, its efficacy in reducing pain amongst RA patients
is favorable for larger research.
Among participant responses considering what they felt to be least effective in
treating their symptoms, maintaining exercise regimens, dietary changes, and attending
therapy were three of the most popular responses. A few respondents reported the use of
non-steroidal medications to be ineffective, while one respondent stated the side effects
of steroids as being a hindrance to their treatment plan (see Question 12). Because most
non-pharmacological approaches entail major changes to the lifestyle, it is
understandable why so many of the participants feel these are the least effective or most
difficult to attain. Changing one’s diet or maintaining an exercise regimen can be
incredibly difficult for healthy adults, let alone for those who are suffering from extreme
pain, fatigue, and inflammation. While the efficacy of these regimens is well known and
supported, their implementation may be easier on paper than in one’s actual lifestyle.
While this may be the case, the effort put in by the participants of this study to try
different treatment approaches should not be overlooked.
To conclude the survey, respondents were asked to compare their pain at the time
of the survey compared to when they were first diagnosed. The final survey questions
were designed to ask the participants to reflect on their journey’s with RA and to reveal
any activities they could no longer pursue due to their symptoms. While three
respondents revealed that they could still pursue all their activities, the majority of
responses revealed that the participants could either no longer do certain activities at all,
or at least not to the extent that they were once able to. Activities like running or hiking
were popular amongst the responses, likely due to the severe impact of these exercises on
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the lower joints. Other activities, such as sewing, which require fine motor movements,
were also common responses (see Question14). Interestingly, compared to when the
participants were first diagnosed, 25% of participants stated they had “no pain,” 32% had
“mild pain,” 39% had “moderate pain,” 4% had “severe pain” and 0% reported “worse
pain” (see Figure 13). Because the majority of patients reported to not be experiencing
levels of ‘severe pain,’ it can be inferred that their treatment plans are contributing to the
improvement of their symptoms. Similarly, 75% of patients reported “yes” to their RA
symptoms currently being under control, while only 7% reported “no” and 18% reported
“other” (see Figure 16). Among the “other” responses, a few patients felt that their
symptoms were only “somewhat” controlled, while others seemed to be able to manage
their pain but were concerned about symptomatic flare-ups.
With the vast number of patients reporting that their RA symptoms are under
control, there is something to be said about the efficacy of their treatment plans. Yet, at
the same time, this survey highlights the struggles faced by many RA patients when it
comes to finalizing a treatment plan, maintaining new regimens, and dealing with the
emotional toll that an RA diagnosis can bring. The need for comprehensive and
personalized interprofessional teams is integral for the treatment of this complex disease.

Limitations
This survey does present a few key limitations. A sample size of only 28
respondents is not sufficient for this data to be considered significant nor can these
findings be generalized to the general population. Survey and response bias may be
present considering the primary researcher and conductor of this survey is also a patient
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with an RA diagnosis. The survey also failed to depict a correlation between participant
responses to allow for a more in-depth analysis of the efficacy of each respondent’s
treatment plans. Along with this, the wording of Question 6 is unclear and does not
define “immediately” in terms of how long it took for the participants to receive an initial
diagnosis after first noticing their symptoms (see Figure 6). The variability of answers to
this question could be misleading. It should also be noted that a few of the research
findings in the literature review are new and forthcoming, thus their reliability is limited.
Finally, the validity and reliability of this survey have not been established.
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CHAPTER THIRTEEN
Conclusion

The treatment for rheumatoid arthritis is variable and especially complex due to
the underlying mechanisms of disease and its manifestations in the non-articular systems
of the body. While it was once considered to strictly be a disease affecting the synovial
linings of the distal joints, the overtly systemic impact of RA on all major systems of the
body is becoming more realized by professionals due to the insights of recent research.
While the pathogenesis and pathophysiology of the disease are still not well-understood,
the implications for how genetic and environmental risk factors may exacerbate the
mechanisms of the disease is central to the current work.
Because RA can show symptoms in the body without the clinical phenotypic
observation of swelling in the distal joints, the results of the literature review reveal the
urgent need for physicians and rheumatologists to explore non-articular patient symptoms
with the insight that these symptoms could indicate the early presence of rheumatoid
arthritis. Observance of the early indicators of disease activity present in the larynx,
lungs, heart, and vascular systems could be transformative in the detection of RA. With
knowledge of how the early detection of this disease can impact a patient’s long-term
prognosis (Hiedari, 2011; Mota et al., 2013), it is inherent for professionals to recognize
the importance of patient symptoms that go beyond pain, fatigue, and joint inflammation.
The optimism demonstrated by the participants of this survey towards the
exploration of non-pharmacological treatment options for RA indicates the need for
further research regarding the efficacy of these treatment options. While the medical
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treatment of RA will surely continue to improve with time, it is in the best interest of all
RA patients to understand the full range of available treatment options. Likewise, the
results of the literature review and patient survey affirm the struggles many RA patients
experience in treating, managing, understanding, and accepting their disease.
The overall findings of this literature review and patient study point towards
adopting a holistic, multifaceted, and interprofessional approach towards the treatment
and chronic evaluation of rheumatoid arthritis. As an autoimmune disease with many
manifestations, RA’s elaborate impact within the body can be life-altering and
devastating. By increasing awareness of the fundamental and unparalleled components of
this disease, there is hope that future research will be directed towards expanding
treatment options and improving the experiences and wellbeing of those who are affected
and impacted by rheumatoid arthritis.
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Appendix D
Patient Survey
Rheumatoid Arthritis Journey – A Patient Survey
Introduction: This research will highlight treatment options and the effectiveness of these
options in treating Rheumatoid Arthritis. The survey will evaluate the treatment
experiences of patients who have been diagnosed with Rheumatoid Arthritis and the
impact of these treatments on their personal medical journeys. To maintain anonymity,
please refrain from using names or any other identifying information in the free response
questions.
1. I have read and understand the previous information regarding my rights as a
research participant.
a. Yes
b. No
Patient Demographics
2. What is your gender?
a. Male
b. Female
c. Other
3. What is your age?
a. 18-22 years old
b. 23-29 years old
c. 30-49 years old
d. 50-64 years old
e. 65 years and older
4. To which racial or ethnic group(s) do you most identify?
a. African-American (non-Hispanic)
b. Asian/Pacific Islander
c. White (non-Hispanic)
d. Latino or Hispanic
e. Native American or Aleut
f. Other (please specify)
Patient Responses to Initial Diagnoses
5. How old were you when you were first diagnosed with Rheumatoid Arthritis?
a. Entry
6. Were you diagnosed immediately after your symptoms first appeared?
a. Yes
b. No
c. Other (please explain)
7. What type of Rheumatoid Arthritis were you diagnosed with?
a. Seropositive
b. Seronegative
c. Juvenile
d. Other (please explain)
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8. How did this diagnosis make you feel?
a. Entry
Patient Responses to Initial Treatment Plans
9. What did your initial treatment plan entail? Check all that apply
a. Pharmacotherapy
b. Holistic remedies
c. Dietary changes
d. Altered exercise regimes
e. Psychosocial interventions
f. Occupational or physical therapy
g. Adaptive equipment
h. Other (please explain)
10. Have you changed the course of your treatment during the duration of your
diagnosis? Why or why not?
a. Entry
11. What have you found to be the most effective in regard to your treatment plan?
a. Entry
12. What have you found to be the least effective or most difficult to attain in regard
to your treatment plan?
a. Entry
Patient Responses Regarding Current Symptoms and Attitudes
13. What have you found to be the least effective or most difficult to attain in regard
to your treatment plan?
a. No pain
b. Mild pain
c. Moderate pain
d. Severe pain
e. Worse pain
14. Are there any activities you can no longer pursue due to you Rheumatoid Arthritis
symptoms?
a. Entry
15. Have you ever discussed how your Rheumatoid Arthritis diagnosis might affect
you personally or socially with your primary care physician?
a. Yes
b. No
c. Other (please explain)
16. Do you currently feel your Rheumatoid Arthritis symptoms are under control?
a. Yes
b. No
c. Other (please explain)
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